Mode
Text Size
Log in / Sign up
N/A N=10 Treatment

A Study to Confirm the Safety of High Frequency DRG Stimulator in Patients With Chronic Lower Limb Pain

Failed Back Surgery Syndrome · Complex Regional Pain Syndrome (CRPS)

Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Jan 2021
Primary outcome: Primary: Safety of Ultrahigh Frequency Treatment: Adverse Event (AE) and Serious AE (SAE) — 5 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
GiMer Medical MN 1000 External Stimulator (Device)
Age
Adult, Older Adult · 20+ yrs
Sex
All
Sponsor
GiMer Medical
Primary completion
Feb 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Safety of Ultrahigh Frequency Treatment: Adverse Event (AE) and Serious AE (SAE)
5
SECONDARY
Change in Pain Measured by Visual Analog Scale (VAS)
-2.7
SECONDARY
Incidence of Paresthesia
SECONDARY
Change in Pain Medication Consumption
3

Summary

This study is a prospective, single-arm, open label, single center pilot study to confirm the safety of a ultrahigh frequency DRG stimulator in patients with chronic lower limb pain. The actual trial length is 5 days. Pts will be given ultrahigh frequency pulse stimulation, and VAS will be obtained after 3-4 hours of each stimulation.

Eligibility Criteria

Inclusion Criteria

  • Age ≧20 and ≦75
  • Have a symptom of complex regional pain syndrome (CRPS), failed back surgery syndrome (FBSS), lower limb pain with or without lower back pain with a diagnosis related to spinal lesion and pain history of >6 months.
  • Have an average pain score >5 by Visual Analogue Scale (VAS) on inclusion.
  • Has failed to achieve adequate pain relief from prior pharmacologic treatments.
  • In the judgement of the investigator, the subject is an appropriate candidate for the trial procedure
  • The subject is willing and able to comply with the procedure and requirements of this trial.
  • The participant is able to understand and provide informed consent, and has signed their written informed consent in accordance with IRB requirements.

Exclusion Criteria

  • Have evidence of a mental or psychological condition that affects pain perception and has difficulty/disability performing objective pain assessment, or have previously failed mental or psychological assessments administered by a psychiatrist that may be deemed to indicate the subject's lack of suitability for participation in this study.
  • Subject has exhibited escalating or changing pain condition within the past 30 days as evidenced by Investigator examination.
  • Be on anticoagulant medication with INR >1.5 or platelet count less than 100,000/μL, peripheral vascular diseases (PVDs), visceral pain or uncontrolled Diabetes mellitus (DM).
  • Has had corticosteroid therapy at an intended site of stimulation within the past 30 days.
  • Pain medication(s) dosages(s) are not stable for at least 30 days.
  • Has previously failed spinal cord stimulation therapy.
  • Currently has an active implantable device including ICD, pacemaker, spinal cord stimulator or intrathecal drug pump or subject requires magnetic resonance imaging (MRIs) or diathermy.
  • Has pain only within a cervical or thoracic distribution.
  • Have a current diagnosis of cancer with active symptoms
  • Have a known terminal illness with life expectancy less than one year
  • Have a systematic or local infection
  • Currently has an indwelling device that may pose an increased risk of infection.
  • Be pregnant or breast feeding
  • Have a medical history of drug or alcohol addiction within the past 2 years.
  • Participation in any investigational study in the last 30 days or current enrollment in any trial.
  • Be currently involved in an injury claim law suit or medically related litigation, including workers compensation.
  • Be a prisoner.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03285113). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search